The Paris stock market is currently gaining nearly 0.5%, around 7780 points, benefiting from the dynamism of Eurofins Scientific (+2.8%), Teleperformance (+2.7%) and STMicro (+2%).

The Parisian index is thus reaching previously unexplored levels. Earlier, the CAC even briefly peaked at 7797 points, its all-time high.

This renewed optimism comes at a time when the many statistics published this week have testified to the robustness of the US economy, but also - to some extent - to the resilience of activity in Europe.

At 2:30 p.m., investors will turn their attention to US producer price figures, a component of the PCE index, the Fed's preferred measure of inflation.

Building permits and housing starts are likely to continue to be penalized by high interest rates, even though mortgage rates have eased since their peak, with hopes of a Fed rate cut.

On the bond front, ten-year Treasuries yielded 4.27% (+3pts), while its European equivalent, the Bund, moved to 2.38% (also +3pts).

The euro was virtually unchanged at $1.0760, while oil prices resumed their upward trend despite the International Energy Agency's downward revision on Thursday of its demand forecasts for 2024.

Brent North Sea crude gave up 0.9% to $82.1 a barrel, while the euro and the dollar remained stable at around $1.076 a barrel.

In other French company news, Tarkett last night published net income, group share of €20.4m in 2023, a far cry from the €26.8m loss recorded in 2022. EPS is thus 0.31 euros, compared with -0.41 euros previously.

This morning, Eutelsat reported net income attributable to the Group of -191.3 million euros for the first half of 2023-24, compared with +51.9 million a year earlier, with an adjusted EBITDA margin of 64.1% at constant exchange rates, compared with 73% a year earlier.

EDF announced a return to profit for the 2023 financial year, boosted by the resumption of nuclear production in France against a backdrop of historically high prices. The state-owned energy company generated operating income (Ebitda) of 39.9 billion euros last year, compared with an operating loss of almost 5 billion euros in 2022.

Orpéa reports that consolidated sales for the full year will amount to 5198 million euros (unaudited figure), up +11% on 2022, of which +9.5% is organic.

Finally, Sanofi announces that the Japanese Ministry of Health has authorized the manufacture and marketing of Dupixent for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 and over, inadequately controlled by existing drugs.

Copyright (c) 2024 All rights reserved.